Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 20Recruiting 4Active not recruiting 3Withdrawn 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 10NIH 5NETWORK 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 2

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Burkitt Lymphoma 2Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

Specimen Handling 39Magnetic Resonance Spectroscopy 30Carboplatin 14Biopsy 14Radiation 13Cyclophosphamide 13Radiotherapy 11daratumumab 10Vincristine 10Dexamethasone 10Surgical Procedures, Operative 9Etoposide 9Lenalidomide 8X-Rays 7Observation 7Leucovorin 7Irinotecan 7Doxorubicin 7Cisplatin 7durvalumab 6dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6Watchful Waiting 6Radiosurgery 6Docetaxel 6Calcium Dobesilate 6pembrolizumab 5Stem Cell Transplantation 5Standard of Care 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × NETWORK × merphos × Clear all
NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT04293562 2026-05-05

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Oncology Group

Phase 3 Recruiting
1,186 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02981628 2026-05-04

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Children's Oncology Group

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Oncology Group

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡